tradingkey.logo

Creative Medical Technology Holdings Inc

CELZ
View Detailed Chart
2.850USD
-0.150-5.00%
Close 11/04, 16:00ETQuotes delayed by 15 min
7.35MMarket Cap
LossP/E TTM

Creative Medical Technology Holdings Inc

2.850
-0.150-5.00%
Intraday
1m
30m
1h
D
W
M
D

Today

-5.00%

5 Days

-49.02%

1 Month

-11.90%

6 Months

+42.50%

Year to Date

+23.38%

1 Year

-18.80%

View Detailed Chart

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Creative Medical Technology Holdings Inc's Score

Industry at a Glance

Industry Ranking
108 / 407
Overall Ranking
225 / 4616
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Buy
Current Rating
20.000
Target Price
+566.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Creative Medical Technology Holdings Inc Highlights

StrengthsRisks
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
Growing
The company is in a growing phase, with the latest annual income totaling USD 11.00K.
Fairly Valued
The company’s latest PE is -0.91, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 71.80K shares, decreasing 74.10% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 17.63K shares of this stock.

Creative Medical Technology Holdings Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Creative Medical Technology Holdings Inc Info

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
Ticker SymbolCELZ
CompanyCreative Medical Technology Holdings Inc
CEOMr. Timothy Warbington
Websitehttps://creativemedicaltechnology.com/
KeyAI